Navigation Links
Pharmaceutical Launch Excellence Services Delivers Market Entry Road Map
Date:3/4/2011

CHAPEL HILL, N.C., March 4, 2011 /PRNewswire/ -- The pressure for a new product to succeed at launch has never been greater with organizations across the pharmaceutical sector facing pipeline deficits, patent expirations and increasing development costs.

Facing an ever-changing launch landscape, product launch leaders are looking to guard against uncertainty as they guide new therapies through the labyrinth of regulatory and marketplace challenges.

To that end, Best Practices, LLC has collected hundreds of best practices, narratives, and metrics around the issue of new product launch. To provide launch executives with the critical information they need to succeed with a product launch, we have consolidated our best launch research and services into the Pharmaceutical Launch Excellence Services.

The Launch Excellence Services product connects launch professionals to benchmarking and networking solutions to address a variety of mission-critical issues, including:

  • Spend across launch activities
  • Differentiating a new product from competitors
  • Portfolio decisions
  • Timing and value of different new product planning activities
  • Coordinating Regional and Global launch activities
  • Strength and weakness of various structural approaches for new product planning
  • Balancing development and commercial interests
  • Brand team responsibilities
  • Use of public relations to support launch

Pharmaceutical executives will find the primary and secondary research information provided in this product essential for identifying trends, gaining a better understanding of the market and ensuring a strong market entry for new products.

To explore the Pharmaceutical Launch Excellence Services in greater detail, download our complimentary research excerpt at http://www3.best-in-class.com/or2.htm.

ABOUT BEST PRACTICES, LLC

Best Practices, LLC serves 48 of the world's 50 top pharmaceutical companies.  For more than 17 years, we have conducted work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies.  For more information about the company, go to www.best-in-class.com.


'/>"/>
SOURCE Best Practices, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results
2. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2010 Financial Results
3. Endo Pharmaceuticals Launches FORTESTA™ (Testosterone) Gel for Topical Use Class III for Adult Men in the U.S. With Low Testosterone
4. Inovio Pharmaceuticals to Present at ROTH 23rd Annual Growth Stock Conference
5. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the Cowen and Company 31st Annual Health Care Conference in Boston on March 9, 2011
6. Onyx Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
7. Savient Pharmaceuticals to Present at the 31st Annual Cowen & Co. Health Care Conference
8. Accumetrics Signs Development & Supply Agreement With Portola Pharmaceuticals, Inc.
9. Handa Pharmaceuticals Announces Submission of Its First-to-File ANDA for Takedas DEXILANT®
10. Auxilium Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
11. Pacira Pharmaceuticals EXPAREL™ Data to be Featured at 2011 ASCPT 112th Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... Global Prostate Cancer Therapeutics Market: Overview ... cancer therapeutics market analyzes the current and future ... prostate cancer, launch of promising emerging therapies, as ... drugs & therapeutic biological products, and high growth ... side effects are some of the drivers expected ...
(Date:4/19/2017)... , April 19, 2017  Sorrento Therapeutics, ... antibody-centric, clinical-stage biopharmaceutical company developing new treatments for ... the closing of its previously announced underwritten public ... at a public offering price of $2.00 per ... estimated offering expenses payable by Sorrento.  The net ...
(Date:4/19/2017)... April 19, 2017  Novartis today announced the ... Heart, Lung, and Blood Institute (NHLBI) of the ... of patients with treatment-naïve severe aplastic anemia (SAA) ... with eltrombopag at the initiation of and concurrently ... evaluated three sequential treatment groups, or cohorts. Cohort ...
Breaking Medicine Technology:
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... ... and laboratory-grade deionized water from the same place. From 101 Water Texas, here ... Satisfaction: Patients and staff can enjoy a continuous supply of pure, fresh, oxygenated ...
(Date:4/23/2017)... CA (PRWEB) , ... April 23, 2017 , ... ... solutions and managed services announced the achievement of Cisco Select certification and SMB ... throughout the United States. , In earning the Select Certification, Altura ...
(Date:4/22/2017)... , ... April 22, 2017 ... ... of Eastern Pennsylvania has named PROSHRED® Security of Philadelphia its “Woman-Owned ... PROSHRED® Philadelphia specializes in providing information destruction , recycling, and ...
(Date:4/22/2017)... PA (PRWEB) , ... April 22, 2017 , ... ... experience to his role as Vice President of Sales and Business Development at ... key GPO/IDN business partner engagements, business development, and strategic planning for the company. ...
(Date:4/21/2017)... ... 21, 2017 , ... An April 10 article in the Daily ... reveal a great deal about prehistoric ice-age dental practitioners and their primitive and, no ... to remove decayed dental matter, and that teeth were then filled with bitumen, a ...
Breaking Medicine News(10 mins):